Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05141279
Collaborator
(none)
50
25

Study Details

Study Description

Brief Summary

The aim of this work to evaluate the accuracy of contrast enhanced spectral mamography in predicting the response to NAC and assessment of residual disease in breast cancer patients

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This a prospective series ,will be performed for 50 patients diagnosed by biopsy as breast cancer who will be scheduled for surgery after completing the full coarse of neoadjuvant chemotherapy

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
    Anticipated Study Start Date :
    Dec 1, 2021
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Jan 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Stable

    2

    Partial response

    3

    Moderate response

    4

    Excellent response

    5

    Complete response

    Outcome Measures

    Primary Outcome Measures

    1. Accuracy of contrast enhanced spectral mamography in the predicting of pathological response to NAC and assessment residual disease in breast cancer patients [Basline]

    Secondary Outcome Measures

    1. Assess best imaging modalities in pedict post neoadjuvant response [Baseline]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • patient confirmed diagnosed by early breast cancer decided to received neoadjuvant treatment

    • locally advanced breast cancer

    • operable metastatic breast cancer

    Exclusion Criteria:
    • patient not candidate for NAC

    • contrast allergy

    • renal impairment

    • pregnancy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    DMAhmed, Doaa Mahmoud Ahmed, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05141279
    Other Study ID Numbers:
    • CESM in breast cancer
    First Posted:
    Dec 2, 2021
    Last Update Posted:
    Dec 2, 2021
    Last Verified:
    Nov 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 2, 2021